References
- Maksymowych W. P. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol 2000; 27: 2295–301
- Braun J., Bollow M., Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24: 697–735
- Urist M. R., Mikulski A., Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci USA 1979; 76: 1828–32
- Reddi A. H. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev 1997; 8: 11–20
- Sampath T. K., Maliakal J. C., Hauschka P. V., Jones W. K., Sasak H., Tucker R. F., et al. Recombinant human osteogenic protein‐1 (hOP‐1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992; 267: 20352–62
- Wolfman N. M., Hattersley G., Cox K., Celeste A. J., Nelson R., Yamaji N., et al. Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF‐beta gene family. J Clin Invest 1997; 100: 321–30
- Carlsen S., Hansson A. S., Olsson H., Heinegard D., Holmdahl R. Cartilage oligomeric matrix protein (COMP)‐induced arthritis in rats. Clin Exp Immunol 1998; 114: 477–84
- Braun J., Baraliakos X., Brandt J., Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005; 34: 178–90
- Braun J., Baraliakos X., Godolias G., Bohm H. Therapy of ankylosing spondylitis – a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005; 34: 97–108
- Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91
- Jenkinson T. R., Mallorie P. A., Whitelock H. C., Kennedy L. G., Garrett S. L., Calin A. Defining spinal mobility in ankylosing spondylitis. The Bath AS Metrology Index. J Rheumatol 1994; 21: 1694–8
- Calin A., Mackay K., Santos H., Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999; 26: 988–92
- Fuchs H. A. The use of the Disease Activity Score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 1993; 20: 1863–6
- Larsen A., Edgren J., Harju E., Laasonen L., Reitamo T. Interobserver variation in the evaluation of radiologic changes of rheumatoid arthritis. Scand J Rheumatol 1979; 8: 109–12
- Flechtenmacher J., Huch K., Thonar E. J., Mollenhauer J. A., Davies S. R., Schmid T. M., et al. Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 1996; 39: 1896–904
- Huch K., Wilbrink B., Flechtenmacher J., Koepp H. E., Aydelotte M. B., Sampath T. K., et al. Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin‐1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin‐1beta. Arthritis Rheum 1997; 40: 2157–61
- Lories R. J. U., Derese I., Luyten F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005; 115: 1571–9